The role of molecular profiling in adrenocortical carcinoma
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-258382
- Adrenocortical carcinoma (ACC) is a rare, aggressive cancer with still partially unknown pathogenesis, heterogenous clinical behaviour and no effective treatment for advanced stages. Therefore, there is an urgent clinical unmet need for better prognostication strategies, innovative therapies and significant improvement of the management of the individual patients. In this review, we summarize available studies on molecular prognostic markers and markers predictive of response to standard therapies as well as newly proposed drug targets inAdrenocortical carcinoma (ACC) is a rare, aggressive cancer with still partially unknown pathogenesis, heterogenous clinical behaviour and no effective treatment for advanced stages. Therefore, there is an urgent clinical unmet need for better prognostication strategies, innovative therapies and significant improvement of the management of the individual patients. In this review, we summarize available studies on molecular prognostic markers and markers predictive of response to standard therapies as well as newly proposed drug targets in sporadic ACC. We include in vitro studies and available clinical trials, focusing on alterations at the DNA, RNA and epigenetic levels. We also discuss the potential of biomarkers to be implemented in a clinical routine workflow for improved ACC patient care.…
Autor(en): | Juliane Lippert, Martin Fassnacht, Cristina L. RonchiORCiD |
---|---|
URN: | urn:nbn:de:bvb:20-opus-258382 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Medizinische Klinik und Poliklinik I |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Clinical Endocrinology |
Erscheinungsjahr: | 2022 |
Band / Jahrgang: | 97 |
Heft / Ausgabe: | 4 |
Seitenangabe: | 460-472 |
Originalveröffentlichung / Quelle: | Clinical Endocrinology (2022) 97:4, 460-472. https://doi.org/10.1111/cen.14629 |
DOI: | https://doi.org/10.1111/cen.14629 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | adrenocortical cancer; biomarkers; precision medicine; prognosis; targeted treatment |
Datum der Freischaltung: | 20.09.2022 |
Lizenz (Deutsch): | CC BY-NC-ND: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell, Keine Bearbeitungen 4.0 International |